Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × Ad26COVS1 × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1 COVID-19 1

Interventions

Gemcitabine 30 pembrolizumab 23 Cyclophosphamide 21 Paclitaxel 19 Irinotecan 18 Carboplatin 18 Docetaxel 17 Capecitabine 17 Fluorouracil 16 fludarabine 13 Leucovorin 13 Bevacizumab 13 Dexamethasone 12 Oxaliplatin 11 Everolimus 11 Erlotinib Hydrochloride 11 Blood Specimen Collection 11 Rituximab 10 Pemetrexed 10 venetoclax 9 Cisplatin 9 Cetuximab 9 Trastuzumab 8 Temozolomide 8 Nivolumab 7 aldesleukin 6 Sunitinib 6 Ipilimumab 6 Interleukin-2 6 Epoetin Alfa 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡